148 related articles for article (PubMed ID: 37812618)
1. Longitudinal measurements of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Muangwong P; Homkham N; Narueban W; Tadadoltip C; Jongjumnien C; Taenawakun N; Teerapattanaphong J; Chitapanarux I
PLoS One; 2023; 18(10):e0292591. PubMed ID: 37812618
[TBL] [Abstract][Full Text] [Related]
2. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P
Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
Chen J; Liu T; Sun Q; Jin T
Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
9. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.
Liu J; Wei C; Tang H; Liu Y; Liu W; Lin C
Medicine (Baltimore); 2020 Jan; 99(2):e18545. PubMed ID: 31914029
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma.
Zhang W; Dou H; Lam C; Liu J; Zhou J; Liu Y; Wang X
Tumour Biol; 2013 Jun; 34(3):1729-36. PubMed ID: 23436047
[TBL] [Abstract][Full Text] [Related]
14. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
16. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y
Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759
[TBL] [Abstract][Full Text] [Related]
17. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
18. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Chua ML; Tan SH; Kusumawidjaja G; Shwe MT; Cheah SL; Fong KW; Soong YL; Wee JT; Tan TW
Eur J Cancer; 2016 Nov; 67():119-129. PubMed ID: 27640138
[TBL] [Abstract][Full Text] [Related]
20. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
